Generali Investments Cee, Investicni Spolecnost, A.S. Alnylam Pharmaceuticals, Inc. Transaction History
Generali Investments Cee, Investicni Spolecnost, A.S.
- $1.07 Trillion
- Q1 2025
A detailed history of Generali Investments Cee, Investicni Spolecnost, A.S. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Generali Investments Cee, Investicni Spolecnost, A.S. holds 2,900 shares of ALNY stock, worth $908,077. This represents 0.07% of its overall portfolio holdings.
Number of Shares
2,900
Previous 2,900
-0.0%
Holding current value
$908,077
Previous $682 Million
14.75%
% of portfolio
0.07%
Previous 0.07%
Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
720Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.24 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.09 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.99 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.24 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.38 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $38.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...